Pharmacology of Insulin and Glucagon

1. Introduction/Overview

The pharmacological management of glucose homeostasis represents a cornerstone of modern endocrinology and metabolic medicine. Insulin and glucagon, two polypeptide hormones secreted by the pancreatic islets of Langerhans, function as primary physiological antagonists in the regulation of fuel metabolism. Their discovery and subsequent therapeutic application have transformed the prognosis of diabetes mellitus from a fatal condition to a manageable chronic disease. The clinical relevance of these agents extends beyond diabetes to include conditions such as hyperkalemia, inotropic support in cardiac emergencies, and diagnostic applications. A thorough understanding of their pharmacology is essential for the rational and safe management of a wide spectrum of metabolic disorders.

Learning Objectives

• Describe the structural classification of insulin and glucagon preparations and their relationship to pharmacokinetic profiles.
• Explain the molecular mechanisms of action for insulin and glucagon, including receptor binding, signal transduction pathways, and resultant metabolic effects.
• Compare and contrast the pharmacokinetic properties of various insulin formulations and glucagon, including absorption, distribution, metabolism, and elimination.
• Identify the approved therapeutic indications, common adverse effects, and significant drug interactions for insulin and glucagon.
• Apply knowledge of special population considerations, such as renal impairment or pregnancy, to dosing and monitoring strategies for these agents.

2. Classification

Insulin and glucagon are classified as peptide hormones. Their therapeutic preparations are derived from recombinant DNA technology, ensuring purity and consistency, and are categorized based on their source, structural modification, and pharmacokinetic profile.

Insulin Classification

Insulin analogs are systematically classified according to their onset, peak, and duration of action, which are primarily determined by amino acid sequence modifications that alter subcutaneous absorption kinetics.

• Rapid-Acting Insulin Analogs: Insulin lispro, insulin aspart, and insulin glulisine. These are characterized by a rapid onset of action (approximately 15 minutes), a peak effect within 1-2 hours, and a duration of 3-5 hours. Modifications involve reversing or substituting charged residues near the C-terminus of the B-chain to prevent hexamer formation, facilitating rapid monomer absorption.
• Short-Acting (Regular) Insulin: Human insulin in a soluble formulation. It has an onset of 30-60 minutes, a peak at 2-3 hours, and a duration of 5-8 hours. It exists as hexamers in the vial which must dissociate into monomers and dimers for absorption, accounting for its slower onset.
• Intermediate-Acting Insulin: Neutral Protamine Hagedorn (NPH) insulin. This is a suspension of insulin complexed with protamine, which delays absorption. Onset occurs in 1-2 hours, peak effect is between 4-10 hours, and duration lasts 10-18 hours.
• Long-Acting Insulin Analogs: Insulin glargine, insulin detemir, and insulin degludec. These provide a relatively peakless basal insulin supply for up to 24 hours or longer. Modifications increase solubility at acidic pH (glargine precipitates in subcutaneous tissue) or promote strong albumin binding (detemir, degludec), resulting in slow, steady release.
• Ultra-Long-Acting Insulin Analogs: Insulin degludec is often categorized separately due to its duration exceeding 42 hours, providing a very stable basal profile with minimal day-to-day variability.
• Premixed Insulin Formulations: Fixed-ratio combinations of a rapid- or short-acting insulin with an intermediate-acting insulin (e.g., 70/30 NPH/regular, 75/25 lispro protamine/lispro).

Glucagon Classification

Glucagon is available in two primary forms based on its indication and route of administration.

• Native Glucagon for Injection: A recombinant peptide identical to human glucagon, supplied as a lyophilized powder for reconstitution. It is used for emergency treatment of severe hypoglycemia and as a diagnostic agent.
• Stable Liquid Glucagon Formulations: More recent developments include stable, ready-to-use liquid glucagon for intramuscular, subcutaneous, or intranasal administration, designed for ease of use in emergency settings.
• Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: While not glucagon itself, this drug class is pharmacologically relevant as it involves receptors related to glucagon. These agents (e.g., liraglutide, semaglutide) are synthetic analogs of the incretin hormone GLP-1 and are used in type 2 diabetes and obesity management.

3. Mechanism of Action

The mechanisms of action for insulin and glucagon involve binding to specific cell surface receptors, initiating complex intracellular signaling cascades that ultimately regulate enzyme activity, gene expression, and cellular transport processes.

Insulin Pharmacodynamics

Insulin exerts its effects by binding to the insulin receptor, a transmembrane tyrosine kinase receptor composed of two extracellular α-subunits and two transmembrane β-subunits. Binding induces a conformational change, leading to autophosphorylation of tyrosine residues on the β-subunits. This activates the receptor’s intrinsic tyrosine kinase activity, which phosphorylates intracellular substrate proteins, primarily the insulin receptor substrates (IRS-1 to IRS-4).

Phosphorylated IRS proteins serve as docking sites for proteins containing Src homology 2 (SH2) domains, initiating two principal signaling pathways:

1. The PI3-Kinase/Akt Pathway: This is the primary metabolic pathway. Phosphatidylinositol 3-kinase (PI3K) is recruited and activated, leading to the generation of phosphatidylinositol (3,4,5)-trisphosphate (PIP₃) at the plasma membrane. PIP₃ recruits phosphoinositide-dependent kinase-1 (PDK1) and Akt (protein kinase B). Activated Akt mediates most of insulin’s metabolic actions:
   • Glucose Uptake: Akt promotes the translocation of glucose transporter type 4 (GLUT4) vesicles from intracellular stores to the plasma membrane in muscle and adipose tissue, facilitating glucose entry.
   • Glycogen Synthesis: Akt phosphorylates and inhibits glycogen synthase kinase-3 (GSK-3), relieving its inhibition of glycogen synthase, thereby promoting glycogen storage.
   • Protein Synthesis: Akt activates the mammalian target of rapamycin complex 1 (mTORC1), stimulating ribosomal biogenesis and translation.
   • Lipid Metabolism: Insulin promotes lipogenesis by activating acetyl-CoA carboxylase and suppressing hormone-sensitive lipase, inhibiting lipolysis.
   • Anti-apoptotic Effects: Akt phosphorylates and inactivates pro-apoptotic factors like Bad and caspase-9.
2. The MAP Kinase Pathway: Activated IRS proteins also recruit Grb2-SOS complexes, activating the Ras/Raf/MEK/ERK cascade. This pathway is more associated with insulin’s mitogenic effects, including cell growth, proliferation, and differentiation.

At the whole-body level, insulin’s actions are anabolic: it lowers blood glucose by increasing cellular uptake, enhances glycogen and triglyceride synthesis, inhibits gluconeogenesis and glycogenolysis in the liver, and promotes protein synthesis while inhibiting proteolysis.

Glucagon Pharmacodynamics

Glucagon acts primarily on hepatocytes by binding to a specific G protein-coupled receptor (GPCR) known as the glucagon receptor. This receptor is coupled predominantly to the stimulatory G protein (G_s).

Receptor activation leads to the dissociation of the G_sα subunit, which then activates adenylate cyclase. Adenylate cyclase catalyzes the conversion of ATP to cyclic adenosine monophosphate (cAMP). The rise in intracellular cAMP activates protein kinase A (PKA). PKA phosphorylates and regulates the activity of key enzymes involved in carbohydrate and lipid metabolism:

• Glycogenolysis: PKA activates phosphorylase kinase, which in turn phosphorylates and activates glycogen phosphorylase, the enzyme responsible for breaking down glycogen to glucose-1-phosphate. Concurrently, PKA phosphorylates and inhibits glycogen synthase, halting glycogen synthesis.
• Gluconeogenesis: PKA promotes gluconeogenesis by upregulating the expression of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase. It also inhibits glycolysis through the phosphorylation and inhibition of pyruvate kinase and phosphofructokinase-2.
• Lipolysis: In adipose tissue, glucagon receptor activation (though less potent than in liver) stimulates hormone-sensitive lipase via the cAMP-PKA pathway, increasing the breakdown of triglycerides to free fatty acids and glycerol.
• Inotropic and Chronotropic Effects: In cardiac muscle, glucagon receptor activation increases cAMP, leading to increased intracellular calcium, which enhances myocardial contractility (positive inotropy) and heart rate (positive chronotropy), independent of β-adrenergic receptors.
• Relaxation of Smooth Muscle: Glucagon causes relaxation of gastrointestinal smooth muscle, a property utilized in diagnostic radiology.

The net physiological effect of glucagon is catabolic and hyperglycemic, mobilizing stored energy to raise blood glucose levels during fasting or stress.

4. Pharmacokinetics

The pharmacokinetic profiles of insulin and glucagon are critical determinants of their clinical use, particularly for insulin, where the timing of action relative to meals and basal needs is paramount.

Insulin Pharmacokinetics

Absorption: All therapeutic insulins, except for regular insulin for intravenous use and inhaled insulin, are administered via subcutaneous injection. Absorption from the subcutaneous tissue is the rate-limiting step and is influenced by multiple factors: insulin formulation (solution vs. suspension), injection site (abdomen absorbs fastest, followed by arm, thigh, and buttock), depth of injection, local blood flow, temperature, and physical activity. Rapid-acting analogs are formulated as clear solutions that exist primarily as monomers, leading to rapid absorption. Long-acting analogs like glargine form microprecipitates or are strongly protein-bound, creating a slow-release depot.

Distribution: Insulin distributes into a volume roughly equivalent to the extracellular fluid volume. It does not cross the blood-brain barrier in significant amounts. Circulating insulin is partially bound to plasma proteins, but the free fraction is pharmacologically active.

Metabolism and Elimination: Insulin is primarily metabolized by enzymatic degradation in the liver and kidneys. Approximately 50-60% of endogenous insulin is cleared by the liver via first-pass metabolism following portal venous delivery. The kidneys metabolize 30-40% through glomerular filtration and subsequent proximal tubular reabsorption and degradation. The metabolic clearance rate is rapid, with a plasma half-life of approximately 4-6 minutes for endogenous insulin. However, the subcutaneous route of administration creates a prolonged absorption phase, making the apparent half-life (reflecting absorption, not elimination) much longer and variable depending on the formulation:

• Rapid-acting: Apparent t_1/2 ~1 hour.
• Short-acting (Regular): Apparent t_1/2 ~1.5 hours.
• Intermediate-acting (NPH): Apparent t_1/2 ~4-6 hours.
• Long-acting (Glargine, Detemir): Apparent t_1/2 ~12-24 hours (dose-dependent for detemir).
• Ultra-long-acting (Degludec): Apparent t_1/2 >25 hours.

Glucagon Pharmacokinetics

Absorption: For emergency hypoglycemia, glucagon is administered intramuscularly or subcutaneously, providing rapid systemic absorption. Intranasal glucagon is also available, absorbed across the nasal mucosa. For diagnostic use (e.g., relaxing the GI tract), it is given intravenously or intramuscularly.

Distribution: Glucagon distributes widely throughout the extracellular space. Its volume of distribution is approximately 0.25 L/kg.

Metabolism and Elimination: Glucagon is catabolized extensively in the liver, kidneys, and plasma. Proteolytic cleavage, particularly at the N-terminus, is a major route of inactivation. Its plasma elimination half-life is very short, approximately 3-6 minutes. The hyperglycemic action following a single intramuscular dose, however, lasts for 60-90 minutes due to the sustained effect on hepatic glucose production.

5. Therapeutic Uses/Clinical Applications

Insulin

• Type 1 Diabetes Mellitus: Lifelong exogenous insulin therapy is mandatory due to absolute insulin deficiency. Regimens typically involve a basal-bolus approach (long-acting basal insulin plus rapid-acting bolus insulin with meals) or continuous subcutaneous insulin infusion (insulin pump).
• Type 2 Diabetes Mellitus: Insulin is initiated when glycemic targets are not achieved with non-insulin antihyperglycemic agents. It may be used as add-on therapy or as the primary agent, starting with basal insulin and progressing to basal-bolus therapy if needed.
• Gestational Diabetes Mellitus: Insulin is the preferred pharmacological agent when medical nutrition therapy fails to achieve glycemic control, as it does not cross the placenta.
• Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS): Continuous intravenous infusion of regular insulin is the standard of care for these acute, life-threatening complications.
• Hyperkalemia: The administration of insulin (usually 10 units regular insulin IV) with glucose (25-50g) promotes intracellular shift of potassium, lowering serum potassium levels acutely. This effect is mediated by insulin’s stimulation of Na⁺/K⁺-ATPase activity.
• Total Parenteral Nutrition (TPN): Insulin is often added to TPN solutions or given separately to manage hyperglycemia in critically ill or surgical patients.

Glucagon

• Severe Hypoglycemia: The primary indication is the treatment of severe hypoglycemia (altered mental status, unconsciousness, inability to ingest oral carbohydrates) in individuals with diabetes. It is a life-saving intervention that can be administered by a caregiver.
• Diagnostic Aid:
  • Radiology: Used as a smooth muscle relaxant to temporarily inhibit gastrointestinal motility during radiographic procedures of the stomach, duodenum, small bowel, and colon.
  • Endocrinology: In the glucagon stimulation test, it is used to assess growth hormone and catecholamine reserve in the evaluation of pituitary insufficiency and pheochromocytoma, respectively.
• β-Blocker and Calcium Channel Blocker Overdose: Glucagon’s positive inotropic and chronotropic effects, mediated via cardiac glucagon receptors and increased cAMP, can be beneficial in overdoses with these cardiotoxic agents, serving as a temporizing measure.
• Investigationally in Obesity: Glucagon receptor agonists and dual agonists targeting both the glucagon and GLP-1 receptors are under investigation for obesity and type 2 diabetes, leveraging glucagon’s effects on increasing energy expenditure and reducing food intake.

6. Adverse Effects

Insulin

• Hypoglycemia: The most common and serious adverse effect. Symptoms range from autonomic (tremor, sweating, palpitations) to neuroglycopenic (confusion, drowsiness, seizure, coma). Risk is increased with erratic meal intake, excessive dosing, exercise, renal impairment, and certain drug interactions.
• Weight Gain: An anabolic effect of insulin therapy, often observed when initiating or intensifying treatment.
• Hypokalemia: Insulin promotes intracellular potassium shift, which can lead to hypokalemia, particularly during treatment of diabetic ketoacidosis.
• Local Injection Site Reactions: Lipohypertrophy (fatty tissue growth) or lipoatrophy (fatty tissue loss) at injection sites. Lipoatrophy is rare with modern human insulin analogs. Erythema, itching, or pain may also occur.
• Allergic Reactions: Rare with recombinant human insulins. Can be local (IgE-mediated) or systemic. Insulin antibodies may develop but are rarely clinically significant.
• Peripheral Edema: Mild sodium and water retention can occur, particularly with initiation of intensive insulin therapy.
• Hypersensitivity: Immediate or delayed-type reactions are possible but uncommon.

Glucagon

• Nausea and Vomiting: Very common, occurring in a significant proportion of patients, likely due to relaxation of the gastrointestinal tract and central effects.
• Hyperglycemia: The intended therapeutic effect in hypoglycemia, but can become excessive if not monitored, especially in patients with residual insulin secretion or if carbohydrates are administered concurrently.
• Hypotension: May occur rarely, possibly due to vasodilation.
• Tachycardia and Hypertension: Due to its positive chronotropic and inotropic effects, glucagon can increase heart rate and blood pressure.
• Allergic Reactions: Including rash, urticaria, and respiratory distress. Anaphylaxis is rare but has been reported, potentially related to protein contaminants in older preparations or excipients.

No black box warnings are currently mandated for standard insulin or glucagon formulations.

7. Drug Interactions

Insulin

Many drugs can affect glycemic control, necessitating careful monitoring and potential dose adjustment.

• Drugs that Potentiate Hypoglycemic Effect (Increase Risk of Hypoglycemia):
  • Oral Antidiabetic Agents: Sulfonylureas, meglitinides, metformin, etc.
  • Antibiotics: Fluoroquinolones (e.g., gatifloxacin, not commonly used), pentamidine.
  • Other: Angiotensin-converting enzyme (ACE) inhibitors, fibrates, monoamine oxidase inhibitors (MAOIs), salicylates (high dose), anabolic steroids, propoxyphene.
  • β-Adrenergic Blockers: Can mask the autonomic warning symptoms of hypoglycemia (tachycardia, tremor) and may impair counter-regulatory responses.
• Drugs that Antagonize Hypoglycemic Effect (Increase Insulin Requirements/Hyperglycemia):
  • Hormones: Corticosteroids, glucagon, growth hormone, thyroid hormones, estrogens, progestins (in oral contraceptives).
  • Sympathomimetics: Epinephrine, albuterol, terbutaline, pseudoephedrine.
  • Other: Thiazide and loop diuretics, phenytoin, niacin (high dose), atypical antipsychotics (e.g., olanzapine, clozapine), protease inhibitors.
• Contraindications: Insulin is contraindicated during episodes of hypoglycemia. There are no absolute contraindications to its use in hyperglycemic states requiring treatment, but caution is required in settings where hypoglycemia risk is extreme.

Glucagon

• β-Blockers: While glucagon is used to treat β-blocker overdose, patients on chronic β-blocker therapy may have a diminished hyperglycemic response to glucagon, as β₂-adrenergic receptors contribute to the counter-regulatory response.
• Insulin and Oral Hypoglycemics: Glucagon is pharmacologically antagonistic to these agents, which is the basis for its use in hypoglycemia.
• Anticholinergics: Concomitant use with glucagon may potentiate gastrointestinal hypomotility and should be used with caution in diagnostic procedures.
• Indomethacin: May blunt the hyperglycemic effect of glucagon.
• Warfarin: Glucagon may potentiate the anticoagulant effect of warfarin, possibly by an unknown mechanism affecting clotting factor synthesis or metabolism. Monitoring of INR is advised.
• Contraindications: Glucagon is contraindicated in patients with pheochromocytoma (risk of catecholamine release), insulinoma (risk of secondary hypoglycemia following initial hyperglycemia), and glucagonoma. Caution is advised in patients with cardiac disease due to potential for tachycardia and hypertension.

8. Special Considerations

Pregnancy and Lactation

Insulin: Insulin is the drug of choice for glycemic control in pregnant women with pre-existing or gestational diabetes. Human insulin and insulin analogs (lispro, aspart, detemir, glargine) are considered safe as they do not cross the placenta in significant amounts. Careful glycemic monitoring and frequent dose adjustments are required due to increasing insulin resistance as pregnancy progresses. Insulin is compatible with breastfeeding; doses may need reduction postpartum due to increased insulin sensitivity and energy expenditure from lactation.

Glucagon: Glucagon is classified as Pregnancy Category B. Data in pregnant women are limited, but it may be used if clearly needed for severe hypoglycemia. It is unknown if glucagon is excreted in human milk; caution is advised if administered to a nursing woman.

Pediatric and Geriatric Populations

Pediatrics: Insulin is the mainstay for type 1 diabetes in children. Dosing is highly individualized based on weight, age, pubertal status, and carbohydrate intake. Rapid-acting analogs are commonly used for meal coverage. Caregiver education on hypoglycemia recognition and management, including glucagon administration, is critical. Glucagon dosing for hypoglycemia is weight-based (20-30 µg/kg or 0.5-1 mg).

Geriatrics: Older adults are at increased risk for hypoglycemia due to potentially irregular meals, polypharmacy, renal impairment, and diminished counter-regulatory hormone responses. Insulin regimens should be simplified when possible, with conservative dosing and avoidance of aggressive glycemic targets. Long-acting analogs with less peak effect may reduce hypoglycemia risk. Glucagon use requires caution due to potential underlying cardiac disease.

Renal and Hepatic Impairment

Renal Impairment: Insulin clearance is reduced in renal failure, increasing the risk of hypoglycemia. Insulin requirements may decrease by 25-50% in advanced chronic kidney disease (CKD) or end-stage renal disease (ESRD). Frequent glucose monitoring and dose reduction are essential. Glucagon is also metabolized by the kidneys; its half-life may be prolonged in renal impairment, potentially extending its hyperglycemic effect.

Hepatic Impairment: The liver is a major site of insulin degradation and the primary target for glucagon. In liver cirrhosis, insulin clearance is decreased and peripheral insulin resistance is often present, making glycemic control unpredictable. Both hyperglycemia and hypoglycemia can occur. Insulin doses may need to be reduced due to decreased clearance, but resistance may increase requirements; careful titration is needed. The hyperglycemic response to glucagon may be blunted in severe liver disease due to diminished glycogen stores and impaired gluconeogenesis.

9. Summary/Key Points

• Insulin and glucagon are antagonistic peptide hormones central to metabolic regulation. Therapeutic preparations are recombinant analogs engineered to modify their pharmacokinetic profiles.
• Insulin acts via a tyrosine kinase receptor, activating the PI3K/Akt pathway to promote glucose uptake, glycogen and lipid synthesis, and protein anabolism. Its pharmacokinetics vary widely among rapid-, short-, intermediate-, long-, and ultra-long-acting formulations.
• Glucagon acts via a G_s-protein coupled receptor, increasing intracellular cAMP and activating PKA to stimulate glycogenolysis, gluconeogenesis, and lipolysis, raising blood glucose.
• Insulin is essential for all type 1 and many type 2 diabetes patients, and is used in hyperkalemia and diabetic emergencies. Glucagon is primarily used for severe hypoglycemia and as a diagnostic aid.
• The most serious adverse effect of insulin is hypoglycemia. Glucagon commonly causes nausea and vomiting. Numerous drug interactions exist for both agents, primarily affecting glycemic control.
• Special consideration is required in pregnancy (insulin is preferred), pediatrics, geriatrics, and in patients with renal or hepatic impairment, often necessitating dose adjustments and enhanced monitoring.

Clinical Pearls

• The “rule of 1500” (or 1800 for rapid-acting analogs) can be used to estimate insulin sensitivity: Total Daily Dose (units) ÷ 1500 gives the expected drop in blood glucose (mg/dL) per unit of rapid-acting insulin.
• When treating severe hypoglycemia with glucagon, the patient should be turned onto their side after administration to prevent aspiration if vomiting occurs.
• Lipohypertrophy at injection sites impairs insulin absorption. Patients must be educated to rotate injection sites systematically.
• In renal impairment, consider using insulin analogs with less renal metabolism (e.g., glargine, detemir) and initiate with markedly reduced doses.
• The hyperglycemic effect of glucagon is transient (60-90 min). Once a patient recovers from severe hypoglycemia, oral carbohydrates must be administered to prevent recurrent hypoglycemia as the glucagon effect wanes.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.